Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

SVB Leerink Downgrades CTI BioPharma to Market Perform, Lowers Price Target to $9.1

Author: Benzinga Newsdesk | May 16, 2023 06:46am
SVB Leerink analyst Andrew Berens downgrades CTI BioPharma (NASDAQ:CTIC) from Outperform to Market Perform and lowers the price target from $13 to $9.1.

Posted In: CTIC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist